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The importance of Helicobacter pylori in the development of gastric 
MALT lymphoma — induction of proliferation and immune suppression
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Marginal zone B-cell lymphomas are indolent, slow-growing lymphomas derived from mature B cells. They represent 
about 8% of all lymphomas and about 50% of all primary gastric lymphomas. Based on numerous epidemiological 
and microbiological studies, Helicobacter pylori is believed to be responsible for the progression of gastric MALT 
lymphomas (GML). Lymphoid tissue is physiologically absent from the stomach. However, GML can arise from 
chronic H. pylori infection and immune cell infiltration. This review article describes the mechanisms favouring the 
development of H. pylori-induced GML, and suggests potential targets for a more effective remission of lymphomas 
localized within the stomach.
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Introduction
Helicobacter pylori is a spiral and gram-negative bac-
terium capable of colonizing the gastric mucosa. This pro-
cess occurs most often during early childhood and lasts 
throughout life in the absence of any adequate eradication 
therapy [1]. Not all people colonized with this bacteria ex-
hibit disease symptoms, but importantly this condition pre-
disposes towards their development [2]. It is estimated that 
over 90% of chronic gastritis is a result of prolonged H. pylori 
infection. Other causes include non-steroidal anti-inflamma-
tory drugs, alcohol consumption, gastroesophageal reflux 
disease and autoimmune mucosa atrophy. Patients with 
gastritis suffer from gastrointestinal disorders which include 
dyspepsia, bloating, discomfort and feeling of fullness in 
the upper abdomen. Symptoms may be aggravated by 
unhealthy diets, alcohol consumption and emotional stress 
or fatigue [3]. The acute phase of H. pylori infection is asso-
ciated with an intense inflammation of the gastric mucosa, 
characterized by infiltration of immune system cells; espe-
cially neutrophils. Increased production of proinflammatory 
cytokines involved in gastric tissue degradation, (including 
IL-1b, IL-6, IL-8, IL-12, TNF-a, CCL2-5, CCL20 and CXCL1-3), is 
the consequence [4]. Inflammatory mediators cause the fol-
lowing: epithelial lesion formation, changes in proliferation 
and apoptosis processes along with modulating host gene 
expression [2]. The acute phase is followed by a decreased 
antimicrobial response of the host organism and chronic 
H. pylori infection. Some people may develop gastric and 
duodenal ulcers, gastric cancer or mucosal associated lym-
phoid tissue (MALT) lymphoma [1].
Characteristics of the MALT lymphoma 
MALT lymphomas can affect the majority of human body 
organs including lungs, thyroid gland, breast, urinary blad-
der and skin [5]. MALT lymphomas are most commonly fo-
und in the digestive system, particularly the stomach, which 
are defined as gastric MALT lymphomas (GML) [6]. GML is an 
indolent extranodal marginal zone B cell lymphoma (MZL). 
The growth of primary gastrointestinal tract lymphomas, 
including gastric lymphoma, is generally slow and limited 
to the gastrointestinal wall; it may remain asymptomatic 
for many years. The morbidity rates of GML increases with 
age. GML are diagnosed mainly in patients aged 60 years 
or over, and GML rates are almost the same for men and 
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Table I. pCR rate within the lymph nodes after preoperative chemotherapy
Study N The rate of pCR in the 
lymph nodes 
ACOSOG Z1071 (cT0–4N1/2)
16 649 41%
SN FNAC (cT0–3N1/2)
17 145 35%
Mamtani (cT0–3N1/2)
18 195 49%
women [7]. MZL are non-Hodgkin lymphomas which evolve 
from mature B cells [8]. Lymphoid tissue is physiologically 
absent from the stomach. However, due to chronic H. pylori 
infection and an infiltration of immune cells, gastric MALT 
lymphomas can arise [9]. MALT lymphoma cells share the 
same cytological and immunophenotypical features: i.e. 
CD20+, CD21+, CD35+, IgM+ and IgD– [10]. MALT lymphomas 
are classified as rare diseases. The annual estimated inciden-
ce of GML is approximately 1–1.5 per 100 000. In comparison, 
gastric cancer is 5 to 10 times more common (United States 
National Cancer Institute Surveillance Epidemiology and 
End Results data) [11]. 
The primary GML diagnosis should be based on clinical 
symptoms and on immunohistochemical and pathohisto-
logical examination of gastric biopsy tissue [11, 12]. Before 
undertaking such examinations, it is important to interview 
the patient, focusing on clinical symptoms that typically 
include: dyspepsia, epigastric pain, nausea, vomiting, we-
ight loss and any alarming symptoms, such as melena and 
hematemesis. Some patients however can remain asymp-
tomatic. The gold standard of the GML diagnostic process 
is an endoscopic examination with multiple biopsies of 
gastric tissue  [7, 8]. Macroscopic changes defined by ga-
stroscopy are nonspecific including thickening of mucosal 
folds and irregular masses with superficial erosions and 
superficial ulcers. Due an equivocal endoscopic picture, 
multiple biopsies are obligatory for pathohistological exa-
mination. Sometimes immunophenotyping and molecular 
examinations may be necessary [8, 12]. 
To evaluate the staging of both Hodgkin and non-Hod-
gkin lymphomas the Ann Arbor system is commonly used. 
However, due to its limitations for assessing primary gas-
trointestinal lymphomas, the Lugano and Radaszkiewicz 
classifications have been proposed [11]. In order to more 
precisely evaluate the staging of primary gastrointestinal 
lymphomas, the European Gastro-Intestinal Lymphoma 
Study Group created The Paris System; a special modifi-
cation of the TNM (tumor-node-metastasis) staging sys-
tem, used for classifying non-hematologic solid malignan-
cies [13]. There are several genetic aberrations characteristic 
to lymphoma cells: translocations, point mutations, gene 
deletions and amplifications. Detecting their presence is 
crucial in the diagnostic process and affects the treatment 
of choice [11]. The genetic aberrations at translocations 
t(1;14) (p22;q32) and t(11;18)(q21;q21) are responsible for 
the response to apoptosis signals being ineffective and 
increased transcriptional activity of NF-kB (nuclear factor 
kappa-light-chain-enhancer of activated B cells). Other 
detected translocations, t(14;18)(q32;q21) and t(3;14)
(p14;q32), are rare and their significance has not yet been 
defined precisely [12]. The most frequent chromosomal 
aberration is the t(11;18) translocation which is detected 
in approximately 20% of patients with MALT lymphoma, 
particularly those with MALT lymphomas located in the 
stomach, colon and lung [5]. 
Expression of H. pylori virulence factors  
and GML development 
Based on numerous epidemiological and microbiolo-
gical studies H. pylori is believed to be responsible for GML 
progression [5, 6]. In a study on 110 patients with GML, 
H. pylori infection was detected in 101 (92%) cases [14]. 
It is believed that H. pylori strains producing multiple vi-
rulence factors are associated with exacerbating gastritis. 
Correlations between the expression of virulence factors, 
especially CagA oncoprotein and VacA toxin, are relatively 
well documented in peptic ulcers and gastric cancer. Ne-
vertheless, their involvement in the development of gastric 
MALT lymphomas remains controversial [6].
The cagPAI pathogenic island is a 40 kb DNA fragment 
containing 27 to 31 genes; eighteen of which encode infor-
mation for proteins forming the IV secretory system (T4SS), 
which facilitates CagA oncoprotein and peptidoglycan 
fragment translocation [2]. CagA is a 120–145 kDa prote-
in produced by 60–70% of H. pylori strains. It rearranges 
the host actin cytoskeleton, disrupts tight junctions and 
causes morphological changes of eukaryotic cells leading 
to the so-called hummingbird phenotype [4]. Moreover, 
CagA inhibits the apoptosis regulator and tumor suppres-
sor — p53, and thus allows B cells to avoid programmed 
death as well as in mediating the accumulation of genetic 
mutations [15].
There are two pathways by which CagA deregulates 
intracellular signalling pathways in eukaryotic cells; i.e. phos-
phorylation-dependent and -independent. The first is based 
on tyrosine phosphorylation within the EPIYA (Glu-Pro-Ile-
Tyr-Ala) motifs of the CagA protein. Modified protein induces 
tyrosine phosphatase 2 (SHP-2) and this activates extra-
cellular signal-regulated kinases 1/2 (Erk1/2). The unphos-
phorylated CagA protein induces Erk1/2 kinase through an 
alternative Ras-Raf signalling pathway [2, 16]. Both processes 
contribute to activating the NF-kB transcription factor and 
increased IL-8 expression [17]. Moreover, peptydoglycan 
fragments delivered through T4SS to host cells also activate 
NF-kB and increase IL-8 secretion by inducing Nod1 proteins 
(nucleotide-binding oligomerization domain 1) [18]. IL-8 is 
not the only chemoattractant for leucocytes but also plays 
an important role as a mitogenic and angiogenic factor in 
neoplasm progression [19]. Erk1/2 stimulation and p53 ex-
pression blockade facilitates apoptosis inhibition which re-
sults in genetically dysfunctional cells being produced. This 
may disrupt homeostasis between programmed cell death 
and proliferative processes together with H. pylori-mediated 
gastric MALT lymphomas development [16]. Ohnishi et al. 
engineered transgenic mice that endogenously produce 
CagA proteins. After 72 weeks from transfection, gastric 
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epithelial hyperplasia was observed and in some individuals 
polyps and adenocarcinomas were detected. Such changes 
have been shown to be due to hyperactivity of SHP-2 phos-
phatase and Erk1/2 kinase [20].
Many epidemiological studies have attempted to eluci-
date any correlation between CagA production by H. pylori 
and the presence of gastric MALT lymphomas. When study-
ing CagA seroprevalence in H. pylori infected patients, Eck 
et al. obtained positive outcomes in 95.5% (64/67) GML 
patients and 67% (33/49) in controls with chronic gastri-
tis [21]. Sumida et al. demonstrated an identical prevalence 
of anti-CagA antibodies, i.e. 95.5% (42/44). Furthermore, it 
was found that patients in GML remission (86.4%; 38/44) 
had significantly higher levels of anti-H. pylori and anti-CagA 
antibodies than in the group without the therapeutic effect; 
respectively 105.2 ± 166.4 vs 24.3 ± 14.9 U/mL and 43.7 
± 25.1 vs 16.5 ± 13.2 U/mL [22]. A study by Delchier et al. 
divided patients into two groups, based on disease progres-
sion, i.e. to low-grade GML (LGML) and diffuse large B-cell 
lymphoma (DLBCL). In the first group, antibodies against 
CagA were detected in 44.8% (13/29) of patients, while 
a higher seroprevalence was found in the DLBCL group of 
75% (12/16) [23]. Similar observations were made by Peng 
et al., who identified cagA through isolating DNA from pa-
tients’ biopsies where gene prevalence was demonstrated 
in 30.3% (17/56) of patients with gastritis, 37.8% (14/37) 
with LGML and 76.7% (23/30) with DLBCL [24]. These results 
suggest that the gastric MALT lymphoma progression may 
be dependent on the expression of cagA by H. pylori strains, 
which is indirectly confirmed by GML treatment effects in 
Hp+ CagA+ patients. Disease remission after eradicating H. 
pylori was found to be faster in patients with CagA+ H. pylori 
infection (average 3 months) than in patients infected with 
CagA- bacterial strains (6.5 months) [25].
The second most important virulence factor produced 
by H. pylori is VacA. All strains of this bacterium have a vacA 
gene but in vitro only half of them synthesize this toxin [6]. 
Three variable regions are present in the vacA sequence, i.e. 
the signal sequence s (s1a, s1b, s1c, s2), the middle region 
m (m1, m2a, m2b) and the intermediate region i (i1, i2, i3). 
The s1/m1/i1 variants have higher biological activity and 
a stronger toxic effect [26]. VacA is a highly immunogenic 
95 kDa protein causing a number of pathological changes 
in the targeted host cells. Among these, is its ability to form 
anion-selective pores in cell membranes, interfere with 
cytoskeleton-dependent cell function and induce apop-
tosis via the mitochondrial cytochrome c release [2, 4]. In 
addition, VacA has in vivo antiproliferative activity against 
lymphocytes and the ability of modulating immune sys-
tem processes [6]. Koehler et al. isolated DNA from biopsy 
samples of H. pylori infected patients with gastritis, gastric 
cancer and GML. It was estimated that in gastric cancer 
patients the dominant H. pylori genotype was vacAs1m1 
(s1 alleles were detected in 93%, 26/28, and m1 in 61%, 
17/28) whilst in the GML group the vacAs1m2 variant was 
dominant (alleles were found in 83%, 20/24, and 83% in 
20/24) [27]. The middle region affects the toxin’s ability to 
interact with targeted cells [26]. Thus the vacAm2 variant 
reduces antiproliferative activity [6]. For this reason, it is 
proposed that the presence of less active VacA toxin forms, 
produced by H. pylori strains, may contribute towards ga-
stric MALT lymphomas developing.
Immune response modulation by H. pylori
Chronic inflammation of the gastric mucosa caused by 
H. pylori infection is probably the key factor responsible for 
GML development. The inflamed gastric mucosa furthers in-
creased antigen presentation and recruitment of B cells [28]. 
Infiltration of these immune cells is accompanied by activat-
ed proliferative processes and the formation of B cell clusters 
and germinal centers (GC) [12, 16]. Moreover, abnormal 
NF-kB pathway activation initiates the transformation of 
gastric lymphoid tissue [12]. The transcription factor NF-kB 
controls B and T cells maturation and survival, exerting an 
anti-apoptotic effect on these cells [29]. Through CagA and 
peptidoglycan fragment translocation, H. pylori increases 
NF-kB activity which results in the host immune response 
being modulated, hyperproliferation of lymphocytes and 
the potential induction of GML [2, 17, 18]. Thereby, chronic 
or recurrent activation of the immune system by H. pylori 
can lead to lymphoid tissue growth. As supported by coex-
isting environmental factors and genetic predispositions 
this process can lead to hyperproliferation of lymphoid 
tissue and oncogenesis [2, 8]. Despite the possibility of B 
cells to undergo autostimulation-dependent activation by 
H. pylori antigens, lymphogenesis may also be mediated by 
T-cell stimulation [6, 12].
The main part of the host lymphocytes induced by 
H. py lori are the Th1 and Th17 populations. The first of these 
secrete proinflammatory cytokines IFN-g and TNF-a, which 
in turn activate antimicrobial activity in macrophages. Th17 
cells also affect progression of the inflammation process 
through secretion of inflammatory mediators such as IL-17A, 
IL-17F, IL-21 and IL-22 [4]. This process is characteristic 
of the initial stages of H. pylori infection. The next step is 
based on the host immune response being suppressed 
by over-activation of CD4+ CD25+ (Treg cells) [9, 30, 31]. 
Treg cells recruitment occurs through secretion of CCL17 
and CCL22 chemokines produced by B cells [32]. Treg cells 
promote tolerogenic signals and secrete anti-inflammatory 
cytokines, such as IL-10 and TGF-b [9, 30]. IL-10 increases 
the B cells ability to proliferate, survive and differentiate. 
On the other hand, these mediators also have antiprolifer-
ative and suppressive effects on other fractions of immune 
cells, i.e. they reduce secretion of proinflammatory IFN-g 
and TNF-a by Th1 cells and of IL-17 by Th17 cells. Such ac-
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tivities promote carcinogenesis via inhibiting secretion of 
antitumor mediators [33]. TGF-b is a cytokine that inhibits 
excessive proliferation and repressor genes encoding for 
cytotoxic mediators, including perforin, granzymes A and 
B and IFN-g [34]. The suppressive environment mediated 
by high TGF-b concentrations affords protection against 
tumours developing. This happens until carcinogenic cells 
become resistant to the stimuli initiated by this mediator, 
for example by the increased activity of mammalian target 
of rapamycin (mTOR), which makes carcinogenic cells in-
sensitive to TGF-b-mediated antiproliferative activity [35]. 
In such situations, elevated TGF-b level is beneficial for 
lymphoma development because it disrupts cytotoxic and 
proapoptotic activity to tumor-altered cells [33]. In an in vivo 
mouse model, Craig et al. demonstrated the ability of Heli-
cobacter spp. to promote MALT lymphoma development by 
Treg cells activation. In H. felis infected BALB/c mice, deple-
tion of CD4+ or CD25+ by monoclonal antibodies resulted 
in tumor regression. After 18 months post-infection, 2–15 
tumors were found in each individual mouse stomach. A dif-
ferent situation was observed in mice lacking CD4+ T cells 
because none had developed lymphoma. In mice without 
CD25+ T cells studies show similar results, excepting one 
individual with a single tumor [32]. Such results suggest 
that Treg cells can actively affect oncogenesis development 
via promoting a suppressive environment that reduces 
antitumor immune system activity.
In addition to the ability for recruiting Treg cells by 
H. pylori, this microorganism may suppress the excessive 
proinflammatory response by promoting high B7/H1 levels. 
These molecules are homologous to immunoglobulins and 
exert an inhibitory effect on programmed death-1 (PD-1) 
receptors on the T cells’ surface. Experiments on tumor cell 
lines have shown that B7/H1 facilitates carcinogenic resi-
stance to apoptosis mediated by Fas-induced cell-death. 
What’s more, H. pylori increases B7/H1 expression which is 
also responsible for the transformation of virgin T cells into 
Treg cells [37]. A study by Lina et al. showed that H. pylori 
increases B7/H1 concentrations which was dependent 
on CagA and peptidoglycan fragment translocation into 
host cells. The in vivo effect of two H. pylori strains on B7/ 
/H1 expression during C57BL/6 mice infection was verified, 
i.e. PMSS1 — producing the T4SS system, and SS1 — ha-
ving no functional T4SS. Enhancement of increased B7/H1 
concentrations was observed only for the H. pylori PPSS1 
strain, which in turn resulted in elevated bacterial growth 
in the mouse and higher amounts of Treg cells and raised 
serum IL-10 [38].
Gastric MALT lymphoma treatment
MALT lymphomas are distinguished by an indolent 
clinical course. Most are diagnosed at an early stage. The-
rapeutical choices depend on whether H. pylori infection 
and the presence of (t11;18) translocation are confirmed; 
the latter being reported as an adverse prognostic factor in 
terms of lymphoma regression after H. pylori eradication [8]. 
Chronic H. pylori infection can lead to lymphoid proliferation 
and GML development. For this reason, H. pylori infection 
should be confirmed in each patient diagnosed with GML. 
The diagnosis should be based on invasive and noninvasive 
tests including measuring IgG, IgM, IgA antibodies, monoc-
lonal stool antigens detection, the 13C-urea breath test, 
microbes culture and histochemical testing [39]. H. pylori 
eradication therapy should rely on highly effective antibio-
tics with due consideration given to possible resistance in 
bacterial strains [5]. Approximately 20% of H. pylori strains 
are proved to be clarithromycin resistant. As a consequen-
ce, it is strongly recommended to attempt an eradication 
by quadruple therapy using a bismuth salt, tetracycline, 
metronidazole and PPI instead of triple therapy using PPI, 
clarithromycin and amoxicillin [40]. H. pylori antibiotic the-
rapy can lead to complete GML remission in 77.5–94% of 
patients [16]. Gastric lymphoma regression in response 
to H. pylori eradication can on average take from 5 to 12 
months and sometimes even 45 months. After achieving 
remission, systematic clinical and endoscopic monitoring is 
mandatory including pathohistological examinations and 
tests for H. pylori infection [7]. The estimated survival rate of 
patients with complete lymphoma remission can reach to 
almost 100% after 10 years. Patients with partial remission 
have a 10-year survival rate of 80% [7, 41]. H. pylori reinfec-
tion determines MALT lymphoma recurrence. In such cases, 
disease progression is more dynamic as a consequence of 
gastric tissue sensitivity to H. pylori antigens [42]. In cases 
when pharmacological treatment fails, radiotherapy should 
be attempted. In patients with aggressive primary GML, i.e. 
large B-cell lymphoma (DLBCL), systemic polychemothe-
rapy is recommended for first-line treatment despite the 
coexisting H. pylori infection. Patients therapy whenever 
advanced-stage disease occurs and in those with confirmed 
lymphoma recurrence is based on chlorambucil, fludarabine 
and rituximab treatment [5, 7, 9, 41].
Implications for medical practice and teaching 
Confirming H. pylori status in people with diagnosed 
GML is a routine procedure [39]. It is suggested that besides 
detecting such bacteria, an important diagnostic element 
may also be in determining the H. pylori virulence profile. 
Such practice is important not only for epidemiological re-
asons (e.g. higher isolation frequency of VacAs1m2 strains), 
but also in planning an effective therapy. It was found that 
GML remission caused by CagA+ H. pylori strains is twice as 
fast as that of CagA- strains [25]. Henceforth, the presence 
of the cagA gene may in future be treated as a microbial 
genetic marker which defines the duration of patient con-
valescence.
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Moreover when toxins production by H. pylori becomes 
known then appropriate compounds can be incorpora-
ted that inhibit pathological metabolic changes in those 
eukaryotic cells exposed to bacterial toxins. Oncoprotein 
CagA induces rearrangement of the host actin cytoskeleton, 
disrupts tight junctions, elicits morphological changes and 
causes malignant transformation [4]. Inhibition of CagA 
kinases in H. pylori infected cells leads to a complete loss of 
CagA phosphorylation and decreases cell death. Pharmaco-
logical inhibition of tyrosine kinases, which mediate CagA 
phosphorylation, may thus become an attractive treatment 
option for patients with late stage GML or in those where 
H. pylori eradication proves unsuccessful [43]. Key molecu-
les responsible for cell-cycle regulation, proliferation and 
apoptosis that are present in the process of MALT lymphoma 
oncogenesis may become specific therapy targets not only 
in patients with this kind of lymphoma, but also in patients 
with other lymphoproliferative disorders [11].
Increased levels of Treg cell recruitment and infiltration 
within tumor-altered stomach tissue is observed [32]. Thus 
in the course of GML, the inflammation intensity correlates 
often inversely with the density of H. pylori found in the 
stomach. On this basis, it can be falsely concluded that the 
absence of a strong inflammatory reaction in the gastric 
mucosa may suggest a low-grade disease. Finding a high 
bacterial titre with low-grade mucosal inflammation may, 
however, indicate the development of the GML process [44]. 
For this reason, attention should be paid to an increased 
oncological vigilance in physicians diagnosing patients 
whenever gastric lymphomas are suspected. 
Elevated Treg cells level in the gastric mucosa is a key 
factor in reducing proliferation and cytotoxic activity of 
other T cells subpopulations, therapeutic failure and a poor 
prognosis [9, 30, 45, 46]. Studies on Treg cell activity during 
an ongoing H. pylori infection may help to find new and 
effective therapies focused on oncogenesis control. The 
course of tumor immunotherapy has shown that Treg-tar-
geting compounds may be good candidates for treatment 
based on immune system modulation. Reducing Treg ac-
tivity promotes the shift of the tumor microenvironment 
from being strongly suppressive to the physiologically 
active [45, 46]. Among potential methods that can achie-
ve this effect are: IL-10 receptor blockade [47], selectin 
blockade [48], inhibition of chemokines responsible for 
Treg cells recruitment (CCL17, CCL22, CCL20 or CXCL13), 
blocking chemokine receptors specifically expressed by 
Treg effector cells (e.g. CCR4), inhibition of CTLR-4 co-in-
hibitory molecules expressed constitutively on the surface 
of Treg cells, or exogenous IL-2 administration (capable 
of reducing suppressive activity of Treg cells) [46]. In ad-
dition to this Treg cell-blocking therapy, it may also prove 
effective to administer low doses of cyclophosphamide. 
Such therapy selectively reduces the amount of rapidly 
proliferating Treg cells within tumor tissue and strengthens 
the anti-tumor response [49].
Conclusions
Numerous studies report a strong association between 
H. pylori gastric mucosa colonization and GML development. 
H. pylori infection mediates Treg cell recruitment, which in 
turn promotes tolerogenic signals and the secretion of an-
ti-inflammatory cytokines IL-10 and TGF-b. In recent years, an 
increasing number of reports suggest a key role of Treg cells 
in perturbing cytotoxic and proapoptotic activity and prob-
ably an effect on GML development. Therefore, decrease 
of the activity or over-recruitment of these immune cells 
appears to be an important target in anti-tumor therapies 
based on enhancing the sensitivity of neoplastic cells. The 
complexity of GML pathogenesis requires extensive knowl-
edge of oncology, microbiology and immunology to ensure 
delivery of effective treatment to the patient. In the light 
of the presented conclusions, close collaboration between 
gastroenterologists, oncologists and microbiologists is thus 
proposed as a standard procedure in the battle against GML.
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